CN109929029A - A method of improving recombinant human blood coagulation factor VII I high efficient expression - Google Patents

A method of improving recombinant human blood coagulation factor VII I high efficient expression Download PDF

Info

Publication number
CN109929029A
CN109929029A CN201711346319.XA CN201711346319A CN109929029A CN 109929029 A CN109929029 A CN 109929029A CN 201711346319 A CN201711346319 A CN 201711346319A CN 109929029 A CN109929029 A CN 109929029A
Authority
CN
China
Prior art keywords
leu
ser
rhfviii
val
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711346319.XA
Other languages
Chinese (zh)
Inventor
肖海鹏
陈英
李利佳
胡育龙
龚庆伟
陈小锋
李文佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Guangdong HEC Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical filed Critical Guangdong HEC Pharmaceutical
Priority to CN201711346319.XA priority Critical patent/CN109929029A/en
Publication of CN109929029A publication Critical patent/CN109929029A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to gene engineering technology fields, specifically a kind of raising recombinant human blood coagulation factor VII I (Recombinant Human Coagulation Factor VIII, referred to as " rhFVIII ") high efficient expression method, a kind of more particularly to method for improving gene recombinant human blood coagulation factor VIII expression quantity in mammalian cells.The present invention makes recombinant human blood coagulation factor VII I high efficient expression by the building and screening of selection Yu the design, recombinant expression plasmid and engineering cell of recombinant human blood coagulation factor VII I gene sequence and using certain density blood serum medium culture positive cell.The method overcome existing cell strain building difficulty, produce the disadvantages of complicated, expression quantity is lower, also have the characteristics that while reducing and researching and developing cost quick, easy, stable, short-cut method is provided for the industrialization transfer of recombinant human blood coagulation factor VII I, the exploitation and Therapy study for biological products have important research and application value.

Description

A method of improving recombinant human blood coagulation factor VII I high efficient expression
Technical field
The present invention relates to gene engineering technology field, specifically a kind of raising recombinant human blood coagulation factor VII I The method of (Recombinant Human Coagulation Factor VIII, referred to as " rhFVIII ") high efficient expression, especially It is related to a kind of method for improving recombinant human blood coagulation factor VII I expression quantity in mammalian cells.
Background technique
Haemophilia A is a kind of common X sex-linked inheritance hemorrhage, 85% is accounted in all hemophilia, morbidity is former Because being found in generation nineteen fifty, in generation nineteen sixty, starts blood extraction and is treated, and the 1970's realized that patient was in self-injection Treatment, the 1980's have broken out patient and have infected hepatitis virus and inhibition of HIV event, generation nineteen ninety start using recombined human blood coagulation because Son treatment recommends daily maintenence treatment to severe haemophiliac since the 2000's.Haemophiliachemophiliac average attack rate is about For 5-10/10 ten thousand, therefore estimate that there are about 400,000 patients in the whole world, there are about 100,000 for China.2014, hemophilia alliance (World Federation of Hemophilia, WFH) the hemophilia number investigation to register on the books is shown, the whole world about 17.85 ten thousand People, and China only has 11108 people and registers on the books.The hemophilia number of every ten thousand population of China is only 0.08, and countries in Europe About 1, the U.S. 0.54, India 0.14, first and last, there is also very big differences for Chinese hemophilia diagnosing and treating coverage rate Away from.
FDA has had been approved by 15 for treating the recombinant human blood coagulation factor VII I of haemophilia A at present (Recombinant Human Coagulation Factor VIII) product.Wherein Advate (hundred because stopping), Kogenate (Bai Keqi), Xyntha (Ren Jie) come into China.The Factor IX sale in the whole world has reached 7,000,000,000 international units year at present, Wherein 60% is genetic engineering recombinant blood coagulation factor VIII.RhFVIII has biological effect similar with haematogenous F8, but Yield is not supplied the generation for the haematogenous virus infection such as being influenced, and avoid HBV, HCV, HIV by blood source, and rhFVIII is in State hemophilia A patients' in use, have preferable effectiveness and reliability.However, approval enters the Bai Keqi and hundred of China Because only expensive, and China can't produce recombinant human blood coagulation factor at present, in addition hemophilia A cannot still cure at present, Therefore it needs to carry out replacement therapy using rhFVIII throughout one's life.So that cost issues become China overwhelming majority haemophilia A patient The major limiting factors for the treatment of, therefore, independent research production rF8 have positive meaning for the satisfaction of domestic patient demand Justice.
The BDD-F8 albumen of eukaryotic cell in vitro expression shows preferable blood coagulation bioactivity, but disadvantage is to be easy drop Solution.In order to improve the expression quantity of rhFVIII and reduce the degradation of albumen, scientist's once cotransfection in mammalian cells RhFVIII and VWF gene stablizes the expression of rhFVIII, but this this method has some limitations.The study found that VWF with RhFVIII coexpression causes exogenous DNA to enter cell overload, and cell strain building is more complicated, while cell co-expresses pressure, Cause the expression quantity of rhFVIII relatively low, stable factors cell strain is subsequent is also difficult to meet industry by high expression vWF filtered out etc. Change and requires.In addition, serum free medium is all used in the culture of cell expression at present, this is because serum-free can avoid serum batch Between the variation of quality, avoid serum from avoiding serum component to experimental study the toxic effect and serum source contact scar of cell Influence and the influence to purifying products.
Summary of the invention
The present invention to solve the above-mentioned problems, improves the expression quantity of rhFVIII, passes through recombinant human blood coagulation factor VII I gene The selection of sequence constructs and screens and provide a kind of culture containing serum with design, recombinant expression plasmid and engineering cell Method realizes the industrialized production of rhFVIII, by being groped serum content, has obtained optimal serum and has been added Amount, the additional amount of serum do not have an impact to isolating and purifying, while keeping the expression of rhFVIII simpler, efficiently.
In order to achieve the above object, the present invention adopts the following technical scheme:
A method of recombinant human blood coagulation factor VII I high efficient expression is improved, is included the following steps:
(1) building of recombination, the recombination include a segment signal peptide gene and rhFVIII gene;
(2) above-mentioned recombination segment is inserted into plasmid, obtains recombinant plasmid;
(3) above-mentioned recombinant plasmid is subjected to PvuI linearisation, electricity is gone in mammalian cell, identified and active survey It is fixed, screen positive cell strain;
(4) by it is above-mentioned screen positive cell strain is seeded in cell culture medium, cultivate 4-5 days, into cell culture medium External source fetal calf serum is added,
It collects culture solution and carries out determination of activity;It is characterized in that, the additional amount of the fetal calf serum is 2-6%.
Further, the rhFVIII gene order in step (1) of the present invention is SEQ ID NO:1.
Preferably, the signal peptide in step (1) of the present invention is reddish black former protein signal peptide (Azu) before killing element, nucleotides sequence It is classified as SEQ ID NO:4, obtaining recombination is Azu-rhFVIII, and nucleotides sequence is classified as SEQ ID NO:6.
Further, the amino acid sequence of recombination Azu-rhFVIII is SEQ ID NO:7.
Preferably, the plasmid in step (2) of the present invention is pXC17.4, and obtained recombinant expression plasmid is pXC17.4- Azu-rhFVIII。
Preferably, the mammalian cell in step (3) of the present invention is Chinese hamster ovary cell CHOK1SV-KO, is obtained Positive cell strain is CHOK1SV-KO/pXC17.4-Azu-rhFVIII.
Preferably, the cell culture medium in step (4) of the present invention is CD CHO AGT culture medium.
Further, the additional amount of fetal calf serum is 3-5% in step (4) of the present invention.
Preferably, the additional amount of fetal calf serum is 3% in step (4) of the present invention.
Further, invention also provides the screening techniques of positive cell strain are as follows: electricity is turned cell inoculation to no blood In clear culture medium, after 35-37 DEG C is cultivated 1 day, supernatant is abandoned in centrifugation, and preheated culture medium (50 μ are added toward cell precipitation Mol/L MSX CD CHO AGT culture medium) it is resuspended, re-suspension liquid is transferred to conical flask and continues to cultivate, is cultivated to after 10 days, sampling By PCR and activity identification, positive cell strain CHOK1SV-KO/pXC17.4-Azu-rhFVIII is screened to obtain.
The invention has the following advantages:
The present invention by building Azu-rhFVIII recombination, be then introduced into plasmid pXC17.4, and by transfect into Mammalian cell CHOK1SV-KO obtains positive cell strain by screening, in the fetal calf serum culture medium containing 2-6% concentration The positive cell strain is cultivated, recombinant human blood coagulation factor VII I is made to obtain stability and high efficiency expression and secretion.
Detailed description of the invention
Fig. 1 is the schematic diagram of recombinant expression plasmid pXC17.4-Azu-rhFVIII.
Fig. 2 is that positive cell Genomic PCR identifies schematic diagram.
Fig. 3 is rhFVIII determination of activity schematic diagram.
Specific embodiment
Term " recombinant human blood coagulation factor VII I " in the present invention and " rhFVIII " unless otherwise instructed, in the present invention For same meaning.
Below with reference to embodiment, the present invention will be further described, but institute's protection scope of the present invention is without being limited thereto.
The building of 1 recombination Azu-rhFVIII of embodiment
1. the full genome of optimization SP and recombinant human blood coagulation factor VII I (SP-rhFVIII) synthesize
According to document (L.Thim, B.Vandahl, J.Karlsson.et al (2010)and characterization of a new recombinant factor VIII(N8).Haemopbilia.16,349-359) The original signal peptide SP (nucleotides sequence is classified as SEQ ID NO:2) of announcement and the amino acid sequence (total 1464aa) of rhFVIII, According to the optimization principles of Chinese hamster ovary cell (CHO), the nucleic acid sequence of SP and rhFVIII are optimized.Simultaneously to sequence In restriction enzyme site carry out considered critical, HindIII, EcoRI, SalI, NotI, PvuI enzyme cannot be contained in the sequence of optimization Enzyme site, while HindIII and Kozak sequence is added to 5 ends ' of sequence, to 3 end ' of sequence add double terminator codons and Then EcoRI, the SP (nucleotides sequence is classified as SEQ ID NO:3) after being optimized obtain coding recombination SP-rhFVIII (nucleotides sequence is classified as SEQ ID NO:5) finally gives gene chemical synthesis company and carries out full genome synthesis (pUC57-SP- rhFVIII)。
2. the reddish black connection for killing former albumen (Azu) and rhFVIII sequence before element
Using the plasmid pUC57-SP-rhFVIII of synthesis as template, by upstream primer F1, (nucleotides sequence is classified as SEQ ID NO:8), containing XbaI restriction enzyme site;Downstream primer F2 (nucleotides sequence is classified as SEQ ID NO:9), contains BglIII digestion position Point.Other reaction solutions are added and carry out PCR, amplification obtains the N-terminal segment A (SEQ ID NO:11,896bp) containing rhFVIII.It connects Contained using HindIII and XbaI enzyme cutting and reddish black kill former albumen (Azurocidin preproprotein: abbreviation Azu) before element Plasmid pXC17.4-Azu-GJC, obtain contain part Azu segment B (SEQ ID NO:12,69bp).Next upstream is utilized Primers F 3 (nucleotides sequence is classified as SEQ ID NO:10), restriction enzyme site containing HindIII;Downstream primer F2 contains BglIII digestion Site carries out over-lap PCR by template of segment A and B, and amplification obtains N-terminal segment C (the SEQ ID containing Azu-rhFVIII NO:13,943bp), segment C is connected to pMD-18T by TA clone, interstitial granules pMD-18T-Azu-rhFVIII (N in acquisition End).
Middle interstitial granules pMD-18T-Azu-rhFVIII (N-terminal) obtains Azu-rhFVIII (N through HindIII and BglII digestion End) segment D (SEQ ID NO:14,937bp), the segment D of acquisition and pUC57-SP-rhFVIII plasmid through HindIII and The carrier segments E (SEQ ID NO:15,6117bp) of BglII double digestion recycling is attached, and obtains positive plasmid pUC57- Azu-rhFVIII(7054bp)。
The building of 2 recombinant expression plasmid pXC17.4-Azu-rhFVIII of embodiment
Obtained positive plasmid pUC57-Azu-rhFVIII is constructed by the way that after HindIII and EcoRII double digestion, recycling contains There is the segment F (SEQ ID NO:16,4413bp) of purpose Gene A zu-rhFVIII, with pXC17.4 through HindIII and EcoRII The carrier segments G (SEQ ID NO:17,6893bp) recycled after double digestion is attached, and screening obtains final recombinant expression plasmid PXC17.4-Azu-rhFVIII (11306 bp), the result is shown in Figure 1.Utilize final purpose Gene A zu-rhFVIII segment The both ends design primer of (4392bp) is sequenced, and sequencing result shows that clone gene segment is consistent with theory.
The acquisition of 3 positive cell CHOK1SV-KO/pXC17.4-Azu-rhFVIII of embodiment
1.pXC17.4-Azu-rhFVIII electrotransformation
Recombinant expression matter pXC17.4-Azu-rhFVIII is linearized using PvuI restriction enzyme site, and by purifying, Filtration sterilization and Sterility testing obtain linearization plasmid pXC17.4-Azu-rhFVIII (concentration 0.4ug/uL).It utilizes simultaneously CD CHO AGT culture medium (L-Gln containing 6mM) recovery and secondary culture CHOK1SV-KO cell, using Lonza company GS XceedTMMethod in Gene Expressions ystem specification prepares CHOK1SV-KO recipient cell, according to default journey Sequence (pulse 300V, 900 μ F, resistance ∞, exponential wave, 4mm gap) shocks by electricity linearization plasmid pXC17.4-Azu-rhFVIII It is transferred to CHOK1SV-KO recipient cell.
2.MSX pressurization screening
After electric shock, by the conical flask for the CD CHO AGT culture medium (without L-Gln) that liquid is transferred in the cup that shocks by electricity It is interior, it after mixing gently, is placed in shaking table, 35-37 DEG C, 140r/min, 8.0%CO2Culture.After cultivating 1d, by all culture solutions It is transferred in 50mL centrifuge tube, supernatant is abandoned in centrifugation (200g, 5min), with preheated culture medium (50 μm of ol/L MSX CD CHO AGT culture medium) it is resuspended, it all moves in conical flask, continues to cultivate.About 10d or so is cultivated, sampling survey vigor is close daily later Degree, until vigor is higher (such as larger than 90%), then preparation freezes and continues secondary culture.
3. positive cell screening and identification
After MSX pressurization screening, the recipient cell of untransfected is being lacked due to lacking endogenic glutamine synthelase Can not be grown in the culture medium of weary L-Gln, the successful engineering cell of plasmid transfection will continued growth go down.Simultaneously by drawing Object F3, restriction enzyme site containing HindIII;Primers F 2 is carried out containing BglIII restriction enzyme site by template of the cellular genome of extraction PCR amplification obtains the DNA fragmentation C being consistent with theoretical size (943bp), as a result sees Fig. 2.Pass through sequencing display amplification piece simultaneously Section is consistent with theory, illustrates that pXC17.4-Azu-rhFVIII is integrated on CHOK1SV-KO genome.Additionally by analysis detection Cells and supernatant, CHOK1SV-KO recipient cell supernatant is without rhFVIII activity, engineering cell CHOK1SV-KO/ as the result is shown PXC17.4-Azu-rhFVIII has rhFVIII active, is shown in Table 1 in detail.
The high efficient expression of 4 recombinant human blood coagulation factor VII I of embodiment
Recovered with the positive cell for screening and identifying, culture 3-4 days after, until cell density reach 1-2 × 106Cells/mL is passed on, and culture to cell density reaches 1~2 × 106Cells/mL obtains seed liquor.By the kind of acquisition Sub- liquid is inoculated into the 1L shaking flask containing CD CHO AGT culture medium, cultivates 4~5 days, the cell density of cell liquid is made to reach 1 ~5 × 106cells/mL;Then external source fetal calf serum is added into cell liquid.Fetal calf serum additional amount and corresponding recombined human Blood coagulation factor VIII expression activity data are shown in Table 1, by the expression quantity of rhFVIII in experimental data, select fetal calf serum addition Optimal addn be 2-6%.
The purifying of 5 recombinant human blood coagulation factor VII I of embodiment and Activity determination
1. the purifying of recombinant human blood coagulation factor VII I
After cell culture fluid passes through low-speed centrifugal (200g, 5min), the supernatant of acquisition further passes through high speed refrigerated centrifuge (8000rpm, 5min, 4 DEG C) obtains purer supernatant.
The determination of activity of 2.rhFVIII
In Ca2 +Under the conditions of existing for phosphatide, Fator X generates Fator Xa, this activation by Fator IXa activation Reaction can greatly be amplified by rhFVIII, by optimizing Ca2 +, phosphatide, Fator IXa and excessive Fator X, The activation rate of Fator X is linear related to rhFVIII.
RhFVIII determination of activity schematic diagram is shown in Fig. 3.
Chromophoric substrate S-2765 (N-a-Z-D-Arg-Gly-Arg-pNA) is the specificity for activating the X factor (factor Xa) Substrate.S-2765 can release chromophore paranitroanilinum (pNA) by Xa factor catalyzing hydrolysis.PNA can be in 405nm wavelength Place detects that the absorption value detected is linear related to rhFVIII, and then can calculate the activity of rhFVIII.
1 recombinant human blood coagulation factor VII I determination of activity result of table
SEQUENCE LISTING
<110>Guangdong Dongyang Guang Pharmaceutical Co., Ltd
<120>a kind of method for improving recombinant human blood coagulation factor VII I high efficient expression
<130> 2017
<160> 17
<170> PatentIn version 3.5
<210> 1
<211> 4335
<212> DNA
<213> Artificial Sequence
<220>
<223> rhFVIII
<400> 1
gccacaaggc ggtactatct gggcgctgtg gaactgtcat gggattacat gcagtccgac 60
ctgggagagc tgccagtgga cgctcgattt ccccctcgtg tccctaagag cttcccattc 120
aacacatctg tggtctataa gaaaacactg ttcgtggagt ttactgatca cctgttcaac 180
atcgccaagc ctaggccacc ctggatggga ctgctgggac caactatcca ggctgaggtg 240
tacgacaccg tggtcattac actgaaaaac atggcatcac acccagtgtc cctgcatgcc 300
gtgggggtct cttactggaa ggctagtgaa ggtgcagagt atgacgatca gacatctcag 360
cgggaaaaag aggacgataa ggtgtttccc ggcggatccc atacttacgt gtggcaggtc 420
ctgaaagaga atggccccat ggcttctgat cctctgtgcc tgacctactc ttatctgagt 480
cacgtggacc tggtcaagga tctgaactcc gggctgatcg gtgcactgct ggtgtgcaga 540
gaagggagcc tggccaagga gaaaacccag acactgcata agttcattct gctgttcgcc 600
gtgtttgacg agggtaaatc atggcactcc gagaccaaga actccctgat gcaggacaga 660
gatgcagcta gcgcccgagc ttggccaaaa atgcatacag tgaacggcta cgtcaatagg 720
agtctgcccg gcctgatcgg atgtcaccgg aagtccgtgt attggcatgt catcgggatg 780
ggtaccacac ccgaagtgca ctctattttc ctggagggac atacctttct ggtccgaaac 840
caccgtcagg caagcctgga gatctctcct attaccttcc tgacagccca gactctgctg 900
atggatctgg ggcagttcct gctgttttgc cacatctcca gccaccagca tgatggtatg 960
gaggcatacg tgaaagtgga ctcctgtccc gaggaacctc agctgagaat gaagaacaat 1020
gaggaagccg aagactatga cgatgacctg actgactccg agatggatgt ggtccgcttc 1080
gatgacgata actccccctc cttcatccag attcgaagcg tggccaagaa acaccccaag 1140
acctgggtcc attacatcgc agccgaggaa gaggactggg attatgcacc actggtgctg 1200
gcaccagacg acaggtccta caaatctcag tatctgaaca atgggcctca gaggatcggt 1260
cggaagtaca agaaagtgcg attcatggcc tataccgatg aaacatttaa gactcgtgaa 1320
gctatccagc acgagtccgg gattctgggt ccactgctgt acggcgaagt gggagacact 1380
ctgctgatca tcttcaagaa ccaggctagc aggccttaca atatctatcc acatggcatt 1440
accgatgtgc ggcctctgta ctctagacgc ctgccaaagg gcgtcaaaca cctgaaggac 1500
ttcccaatcc tgcccggaga aatcttcaag tataaatgga ctgtcaccgt cgaggatgga 1560
cccactaagt ctgaccctag gtgcctgacc cggtactatt ctagtttcgt gaatatggaa 1620
agggatctgg cctccgggct gatcggtcca ctgctgattt gttacaaaga gtctgtggat 1680
cagcgaggca accagatcat gagtgacaag cgtaatgtga ttctgttctc cgtctttgac 1740
gaaaacagaa gctggtatct gaccgagaac atccagaggt tcctgcctaa tccagcaggc 1800
gtgcagctgg aagatcccga gtttcaggcc tcaaacatca tgcattccat taatggatac 1860
gtgttcgaca gtctgcagct gtcagtgtgc ctgcacgagg tcgcctactg gtatatcctg 1920
tccattgggg ctcagacaga tttcctgtcc gtgttcttta gcggttacac tttcaagcat 1980
aagatggtct acgaggacac actgactctg ttcccttttt ctggcgaaac cgtgtttatg 2040
agtatggaga atccaggcct gtggatcctg ggatgccaca acagcgattt ccgaaatcgt 2100
ggcatgactg ctctgctgaa agtgtcatcc tgtgacaaga acaccggaga ctactatgaa 2160
gatagctacg aggacatctc tgcttatctg ctgagtaaga acaatgcaat tgaacccagg 2220
tcttttagtc agaactctcg gcatcctagt cagaatcctc cagtgctgaa gagacaccag 2280
cgcgagatca ctagaactac cctgcagagt gatcaggaag agatcgacta cgacgatacc 2340
atttccgtgg aaatgaagaa agaggacttc gatatctatg acgaagatga gaaccagagt 2400
cctagatcat tccagaagaa aacccgccat tactttattg ctgcagtgga gcgcctgtgg 2460
gattatggga tgagctctag tccccacgtg ctgaggaatc gggcccagtc aggttccgtc 2520
cctcagttca agaaagtggt cttccaggag tttacagacg gcagctttac tcagcctctg 2580
tacagaggag aactgaacga gcacctgggc ctgctgggac catatatccg cgccgaagtg 2640
gaggataaca ttatggtcac cttccgaaat caggcttcac gtccctactc cttttattca 2700
tccctgatct cttacgaaga ggaccagcga cagggcgctg aaccccgtaa aaacttcgtg 2760
aagcctaatg agaccaaaac atacttttgg aaggtgcagc accatatggc ccctacaaaa 2820
gacgagttcg attgcaaggc atgggcctat ttttcagacg tggatctgga gaaggacgtg 2880
cactctgggc tgatcggtcc tctgctggtg tgccatacta acaccctgaa tccagctcac 2940
ggcaggcagg tgacagtcca ggagttcgca ctgttcttta ccatctttga tgagacaaag 3000
tcctggtact tcactgaaaa catggagcga aattgccgtg ctccatgtaa tattcagatg 3060
gaagacccca ccttcaagga gaactaccgg tttcatgcaa tcaatggcta tattatggat 3120
acactgccag gactggtgat ggcccaggac cagagaatcc gctggtacct gctgtccatg 3180
ggcagcaacg agaatatcca cagcattcat ttctctggac acgtgtttac agtccgcaag 3240
aaagaagagt ataaaatggc cctgtacaac ctgtatccag gggtgttcga aactgtcgag 3300
atgctgccca gcaaggctgg tatctggcga gtggaatgcc tgattgggga gcacctgcat 3360
gcaggcatgt caaccctgtt tctggtgtac tccaataagt gtcagacacc actggggatg 3420
gccagcggtc atatccgaga tttccagatt accgcttctg gccagtacgg acagtgggcc 3480
cccaagctgg ctaggctgca ctatagcggc tctatcaacg cctggagtac caaagagccc 3540
ttttcatgga ttaaggtgga cctgctggct cctatgatca ttcatgggat caaaacacag 3600
ggtgcacggc agaagttcag ctctctgtac atcagccagt tcatcatcat gtactctctg 3660
gatggaaaga aatggcagac atacagaggc aatagcacag gaactctgat ggtgttcttt 3720
ggcaacgtgg acagttcagg aatcaagcac aacattttca atccccctat cattgctagg 3780
tacatccggc tgcaccctac ccattattct attagaagta cactgcgcat ggaactgatg 3840
gggtgcgatc tgaacagttg ttcaatgcca ctgggtatgg agagtaaggc aatctcagac 3900
gcccagatta ccgcttccag ctacttcact aatatgtttg ctacctggtc ccctagcaaa 3960
gcaagactgc atctgcaggg caggagcaac gcatggcggc cacaggtgaa caatcccaag 4020
gagtggctgc aggtcgattt tcagaaaact atgaaggtga ccggcgtcac aactcaggga 4080
gtgaaatccc tgctgactag catgtatgtc aaggagttcc tgatctctag ttcacaggac 4140
ggacaccagt ggaccctgtt ctttcagaac gggaaggtga aagtcttcca gggtaatcag 4200
gatagtttta cacccgtggt caactcactg gacccacccc tgctgactag atacctgcgc 4260
atccaccctc agtcttgggt gcatcagatt gctctgagga tggaagtcct gggctgtgag 4320
gcacaggacc tgtat 4335
<210> 2
<211> 57
<212> DNA
<213> artificial sequence
<220>
<223>SP before optimizing
<400> 2
atgcaaatag agctctccac ctgcttcttt ctgtgccttt tgcgattctg ctttagt 57
<210> 3
<211> 57
<212> DNA
<213> artificial sequence
<220>
<223>SP after optimizing
<400> 3
atgcagatcg agctgagcac ctgcttcttc ctgtgcctgc tgcggttctg cttttct 57
<210> 4
<211> 57
<212> DNA
<213> artificial sequence
<220>
<223> Azu
<400> 4
atgaccagac tgaccgtgct ggctctgctg gccggactgc tggcttcttc tagagcc 57
<210> 5
<211> 4392
<212> DNA
<213> artificial sequence
<220>
<223>SP+rhFVIII after optimizing
<400> 5
atgcagatcg agctgagcac ctgcttcttc ctgtgcctgc tgcggttctg cttttctgcc 60
acaaggcggt actatctggg cgctgtggaa ctgtcatggg attacatgca gtccgacctg 120
ggagagctgc cagtggacgc tcgatttccc cctcgtgtcc ctaagagctt cccattcaac 180
acatctgtgg tctataagaa aacactgttc gtggagttta ctgatcacct gttcaacatc 240
gccaagccta ggccaccctg gatgggactg ctgggaccaa ctatccaggc tgaggtgtac 300
gacaccgtgg tcattacact gaaaaacatg gcatcacacc cagtgtccct gcatgccgtg 360
ggggtctctt actggaaggc tagtgaaggt gcagagtatg acgatcagac atctcagcgg 420
gaaaaagagg acgataaggt gtttcccggc ggatcccata cttacgtgtg gcaggtcctg 480
aaagagaatg gccccatggc ttctgatcct ctgtgcctga cctactctta tctgagtcac 540
gtggacctgg tcaaggatct gaactccggg ctgatcggtg cactgctggt gtgcagagaa 600
gggagcctgg ccaaggagaa aacccagaca ctgcataagt tcattctgct gttcgccgtg 660
tttgacgagg gtaaatcatg gcactccgag accaagaact ccctgatgca ggacagagat 720
gcagctagcg cccgagcttg gccaaaaatg catacagtga acggctacgt caataggagt 780
ctgcccggcc tgatcggatg tcaccggaag tccgtgtatt ggcatgtcat cgggatgggt 840
accacacccg aagtgcactc tattttcctg gagggacata cctttctggt ccgaaaccac 900
cgtcaggcaa gcctggagat ctctcctatt accttcctga cagcccagac tctgctgatg 960
gatctggggc agttcctgct gttttgccac atctccagcc accagcatga tggtatggag 1020
gcatacgtga aagtggactc ctgtcccgag gaacctcagc tgagaatgaa gaacaatgag 1080
gaagccgaag actatgacga tgacctgact gactccgaga tggatgtggt ccgcttcgat 1140
gacgataact ccccctcctt catccagatt cgaagcgtgg ccaagaaaca ccccaagacc 1200
tgggtccatt acatcgcagc cgaggaagag gactgggatt atgcaccact ggtgctggca 1260
ccagacgaca ggtcctacaa atctcagtat ctgaacaatg ggcctcagag gatcggtcgg 1320
aagtacaaga aagtgcgatt catggcctat accgatgaaa catttaagac tcgtgaagct 1380
atccagcacg agtccgggat tctgggtcca ctgctgtacg gcgaagtggg agacactctg 1440
ctgatcatct tcaagaacca ggctagcagg ccttacaata tctatccaca tggcattacc 1500
gatgtgcggc ctctgtactc tagacgcctg ccaaagggcg tcaaacacct gaaggacttc 1560
ccaatcctgc ccggagaaat cttcaagtat aaatggactg tcaccgtcga ggatggaccc 1620
actaagtctg accctaggtg cctgacccgg tactattcta gtttcgtgaa tatggaaagg 1680
gatctggcct ccgggctgat cggtccactg ctgatttgtt acaaagagtc tgtggatcag 1740
cgaggcaacc agatcatgag tgacaagcgt aatgtgattc tgttctccgt ctttgacgaa 1800
aacagaagct ggtatctgac cgagaacatc cagaggttcc tgcctaatcc agcaggcgtg 1860
cagctggaag atcccgagtt tcaggcctca aacatcatgc attccattaa tggatacgtg 1920
ttcgacagtc tgcagctgtc agtgtgcctg cacgaggtcg cctactggta tatcctgtcc 1980
attggggctc agacagattt cctgtccgtg ttctttagcg gttacacttt caagcataag 2040
atggtctacg aggacacact gactctgttc cctttttctg gcgaaaccgt gtttatgagt 2100
atggagaatc caggcctgtg gatcctggga tgccacaaca gcgatttccg aaatcgtggc 2160
atgactgctc tgctgaaagt gtcatcctgt gacaagaaca ccggagacta ctatgaagat 2220
agctacgagg acatctctgc ttatctgctg agtaagaaca atgcaattga acccaggtct 2280
tttagtcaga actctcggca tcctagtcag aatcctccag tgctgaagag acaccagcgc 2340
gagatcacta gaactaccct gcagagtgat caggaagaga tcgactacga cgataccatt 2400
tccgtggaaa tgaagaaaga ggacttcgat atctatgacg aagatgagaa ccagagtcct 2460
agatcattcc agaagaaaac ccgccattac tttattgctg cagtggagcg cctgtgggat 2520
tatgggatga gctctagtcc ccacgtgctg aggaatcggg cccagtcagg ttccgtccct 2580
cagttcaaga aagtggtctt ccaggagttt acagacggca gctttactca gcctctgtac 2640
agaggagaac tgaacgagca cctgggcctg ctgggaccat atatccgcgc cgaagtggag 2700
gataacatta tggtcacctt ccgaaatcag gcttcacgtc cctactcctt ttattcatcc 2760
ctgatctctt acgaagagga ccagcgacag ggcgctgaac cccgtaaaaa cttcgtgaag 2820
cctaatgaga ccaaaacata cttttggaag gtgcagcacc atatggcccc tacaaaagac 2880
gagttcgatt gcaaggcatg ggcctatttt tcagacgtgg atctggagaa ggacgtgcac 2940
tctgggctga tcggtcctct gctggtgtgc catactaaca ccctgaatcc agctcacggc 3000
aggcaggtga cagtccagga gttcgcactg ttctttacca tctttgatga gacaaagtcc 3060
tggtacttca ctgaaaacat ggagcgaaat tgccgtgctc catgtaatat tcagatggaa 3120
gaccccacct tcaaggagaa ctaccggttt catgcaatca atggctatat tatggataca 3180
ctgccaggac tggtgatggc ccaggaccag agaatccgct ggtacctgct gtccatgggc 3240
agcaacgaga atatccacag cattcatttc tctggacacg tgtttacagt ccgcaagaaa 3300
gaagagtata aaatggccct gtacaacctg tatccagggg tgttcgaaac tgtcgagatg 3360
ctgcccagca aggctggtat ctggcgagtg gaatgcctga ttggggagca cctgcatgca 3420
ggcatgtcaa ccctgtttct ggtgtactcc aataagtgtc agacaccact ggggatggcc 3480
agcggtcata tccgagattt ccagattacc gcttctggcc agtacggaca gtgggccccc 3540
aagctggcta ggctgcacta tagcggctct atcaacgcct ggagtaccaa agagcccttt 3600
tcatggatta aggtggacct gctggctcct atgatcattc atgggatcaa aacacagggt 3660
gcacggcaga agttcagctc tctgtacatc agccagttca tcatcatgta ctctctggat 3720
ggaaagaaat ggcagacata cagaggcaat agcacaggaa ctctgatggt gttctttggc 3780
aacgtggaca gttcaggaat caagcacaac attttcaatc cccctatcat tgctaggtac 3840
atccggctgc accctaccca ttattctatt agaagtacac tgcgcatgga actgatgggg 3900
tgcgatctga acagttgttc aatgccactg ggtatggaga gtaaggcaat ctcagacgcc 3960
cagattaccg cttccagcta cttcactaat atgtttgcta cctggtcccc tagcaaagca 4020
agactgcatc tgcagggcag gagcaacgca tggcggccac aggtgaacaa tcccaaggag 4080
tggctgcagg tcgattttca gaaaactatg aaggtgaccg gcgtcacaac tcagggagtg 4140
aaatccctgc tgactagcat gtatgtcaag gagttcctga tctctagttc acaggacgga 4200
caccagtgga ccctgttctt tcagaacggg aaggtgaaag tcttccaggg taatcaggat 4260
agttttacac ccgtggtcaa ctcactggac ccacccctgc tgactagata cctgcgcatc 4320
caccctcagt cttgggtgca tcagattgct ctgaggatgg aagtcctggg ctgtgaggca 4380
caggacctgt at 4392
<210> 6
<211> 4392
<212> DNA
<213> artificial sequence
<220>
<223> Azu+rhFVIII
<400> 6
atgaccagac tgaccgtgct ggctctgctg gccggactgc tggcttcttc tagagccgcc 60
acaaggcggt actatctggg cgctgtggaa ctgtcatggg attacatgca gtccgacctg 120
ggagagctgc cagtggacgc tcgatttccc cctcgtgtcc ctaagagctt cccattcaac 180
acatctgtgg tctataagaa aacactgttc gtggagttta ctgatcacct gttcaacatc 240
gccaagccta ggccaccctg gatgggactg ctgggaccaa ctatccaggc tgaggtgtac 300
gacaccgtgg tcattacact gaaaaacatg gcatcacacc cagtgtccct gcatgccgtg 360
ggggtctctt actggaaggc tagtgaaggt gcagagtatg acgatcagac atctcagcgg 420
gaaaaagagg acgataaggt gtttcccggc ggatcccata cttacgtgtg gcaggtcctg 480
aaagagaatg gccccatggc ttctgatcct ctgtgcctga cctactctta tctgagtcac 540
gtggacctgg tcaaggatct gaactccggg ctgatcggtg cactgctggt gtgcagagaa 600
gggagcctgg ccaaggagaa aacccagaca ctgcataagt tcattctgct gttcgccgtg 660
tttgacgagg gtaaatcatg gcactccgag accaagaact ccctgatgca ggacagagat 720
gcagctagcg cccgagcttg gccaaaaatg catacagtga acggctacgt caataggagt 780
ctgcccggcc tgatcggatg tcaccggaag tccgtgtatt ggcatgtcat cgggatgggt 840
accacacccg aagtgcactc tattttcctg gagggacata cctttctggt ccgaaaccac 900
cgtcaggcaa gcctggagat ctctcctatt accttcctga cagcccagac tctgctgatg 960
gatctggggc agttcctgct gttttgccac atctccagcc accagcatga tggtatggag 1020
gcatacgtga aagtggactc ctgtcccgag gaacctcagc tgagaatgaa gaacaatgag 1080
gaagccgaag actatgacga tgacctgact gactccgaga tggatgtggt ccgcttcgat 1140
gacgataact ccccctcctt catccagatt cgaagcgtgg ccaagaaaca ccccaagacc 1200
tgggtccatt acatcgcagc cgaggaagag gactgggatt atgcaccact ggtgctggca 1260
ccagacgaca ggtcctacaa atctcagtat ctgaacaatg ggcctcagag gatcggtcgg 1320
aagtacaaga aagtgcgatt catggcctat accgatgaaa catttaagac tcgtgaagct 1380
atccagcacg agtccgggat tctgggtcca ctgctgtacg gcgaagtggg agacactctg 1440
ctgatcatct tcaagaacca ggctagcagg ccttacaata tctatccaca tggcattacc 1500
gatgtgcggc ctctgtactc tagacgcctg ccaaagggcg tcaaacacct gaaggacttc 1560
ccaatcctgc ccggagaaat cttcaagtat aaatggactg tcaccgtcga ggatggaccc 1620
actaagtctg accctaggtg cctgacccgg tactattcta gtttcgtgaa tatggaaagg 1680
gatctggcct ccgggctgat cggtccactg ctgatttgtt acaaagagtc tgtggatcag 1740
cgaggcaacc agatcatgag tgacaagcgt aatgtgattc tgttctccgt ctttgacgaa 1800
aacagaagct ggtatctgac cgagaacatc cagaggttcc tgcctaatcc agcaggcgtg 1860
cagctggaag atcccgagtt tcaggcctca aacatcatgc attccattaa tggatacgtg 1920
ttcgacagtc tgcagctgtc agtgtgcctg cacgaggtcg cctactggta tatcctgtcc 1980
attggggctc agacagattt cctgtccgtg ttctttagcg gttacacttt caagcataag 2040
atggtctacg aggacacact gactctgttc cctttttctg gcgaaaccgt gtttatgagt 2100
atggagaatc caggcctgtg gatcctggga tgccacaaca gcgatttccg aaatcgtggc 2160
atgactgctc tgctgaaagt gtcatcctgt gacaagaaca ccggagacta ctatgaagat 2220
agctacgagg acatctctgc ttatctgctg agtaagaaca atgcaattga acccaggtct 2280
tttagtcaga actctcggca tcctagtcag aatcctccag tgctgaagag acaccagcgc 2340
gagatcacta gaactaccct gcagagtgat caggaagaga tcgactacga cgataccatt 2400
tccgtggaaa tgaagaaaga ggacttcgat atctatgacg aagatgagaa ccagagtcct 2460
agatcattcc agaagaaaac ccgccattac tttattgctg cagtggagcg cctgtgggat 2520
tatgggatga gctctagtcc ccacgtgctg aggaatcggg cccagtcagg ttccgtccct 2580
cagttcaaga aagtggtctt ccaggagttt acagacggca gctttactca gcctctgtac 2640
agaggagaac tgaacgagca cctgggcctg ctgggaccat atatccgcgc cgaagtggag 2700
gataacatta tggtcacctt ccgaaatcag gcttcacgtc cctactcctt ttattcatcc 2760
ctgatctctt acgaagagga ccagcgacag ggcgctgaac cccgtaaaaa cttcgtgaag 2820
cctaatgaga ccaaaacata cttttggaag gtgcagcacc atatggcccc tacaaaagac 2880
gagttcgatt gcaaggcatg ggcctatttt tcagacgtgg atctggagaa ggacgtgcac 2940
tctgggctga tcggtcctct gctggtgtgc catactaaca ccctgaatcc agctcacggc 3000
aggcaggtga cagtccagga gttcgcactg ttctttacca tctttgatga gacaaagtcc 3060
tggtacttca ctgaaaacat ggagcgaaat tgccgtgctc catgtaatat tcagatggaa 3120
gaccccacct tcaaggagaa ctaccggttt catgcaatca atggctatat tatggataca 3180
ctgccaggac tggtgatggc ccaggaccag agaatccgct ggtacctgct gtccatgggc 3240
agcaacgaga atatccacag cattcatttc tctggacacg tgtttacagt ccgcaagaaa 3300
gaagagtata aaatggccct gtacaacctg tatccagggg tgttcgaaac tgtcgagatg 3360
ctgcccagca aggctggtat ctggcgagtg gaatgcctga ttggggagca cctgcatgca 3420
ggcatgtcaa ccctgtttct ggtgtactcc aataagtgtc agacaccact ggggatggcc 3480
agcggtcata tccgagattt ccagattacc gcttctggcc agtacggaca gtgggccccc 3540
aagctggcta ggctgcacta tagcggctct atcaacgcct ggagtaccaa agagcccttt 3600
tcatggatta aggtggacct gctggctcct atgatcattc atgggatcaa aacacagggt 3660
gcacggcaga agttcagctc tctgtacatc agccagttca tcatcatgta ctctctggat 3720
ggaaagaaat ggcagacata cagaggcaat agcacaggaa ctctgatggt gttctttggc 3780
aacgtggaca gttcaggaat caagcacaac attttcaatc cccctatcat tgctaggtac 3840
atccggctgc accctaccca ttattctatt agaagtacac tgcgcatgga actgatgggg 3900
tgcgatctga acagttgttc aatgccactg ggtatggaga gtaaggcaat ctcagacgcc 3960
cagattaccg cttccagcta cttcactaat atgtttgcta cctggtcccc tagcaaagca 4020
agactgcatc tgcagggcag gagcaacgca tggcggccac aggtgaacaa tcccaaggag 4080
tggctgcagg tcgattttca gaaaactatg aaggtgaccg gcgtcacaac tcagggagtg 4140
aaatccctgc tgactagcat gtatgtcaag gagttcctga tctctagttc acaggacgga 4200
caccagtgga ccctgttctt tcagaacggg aaggtgaaag tcttccaggg taatcaggat 4260
agttttacac ccgtggtcaa ctcactggac ccacccctgc tgactagata cctgcgcatc 4320
caccctcagt cttgggtgca tcagattgct ctgaggatgg aagtcctggg ctgtgaggca 4380
caggacctgt at 4392
<210> 7
<211> 1464
<212> PRT
<213> artificial sequence
<220>
<223>Azu+rhFVIII amino acid sequence
<400> 7
Met Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe
1 5 10 15
Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser
20 25 30
Trp Asp Tyr Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala Arg
35 40 45
Phe Pro Pro Arg Val Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val
50 55 60
Tyr Lys Lys Thr Leu Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile
65 70 75 80
Ala Lys Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln
85 90 95
Ala Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser
100 105 110
His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser
115 120 125
Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp
130 135 140
Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu
145 150 155 160
Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser
165 170 175
Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile
180 185 190
Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr
195 200 205
Gln Thr Leu His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly
210 215 220
Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp
225 230 235 240
Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr
245 250 255
Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val
260 265 270
Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile
275 280 285
Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser
290 295 300
Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met
305 310 315 320
Asp Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His
325 330 335
Asp Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro
340 345 350
Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp
355 360 365
Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser
370 375 380
Pro Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr
385 390 395 400
Trp Val His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro
405 410 415
Leu Val Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn
420 425 430
Asn Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met
435 440 445
Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu
450 455 460
Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr Leu
465 470 475 480
Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro
485 490 495
His Gly Ile Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys
500 505 510
Gly Val Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe
515 520 525
Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp
530 535 540
Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg
545 550 555 560
Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu
565 570 575
Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val
580 585 590
Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu
595 600 605
Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp
610 615 620
Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val
625 630 635 640
Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp
645 650 655
Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe
660 665 670
Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr
675 680 685
Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro
690 695 700
Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly
705 710 715 720
Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp
725 730 735
Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys
740 745 750
Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg His Pro
755 760 765
Ser Gln Asn Pro Pro Val Leu Lys Arg His Gln Arg Glu Ile Thr Arg
770 775 780
Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr Asp Asp Thr Ile
785 790 795 800
Ser Val Glu Met Lys Lys Glu Asp Phe Asp Ile Tyr Asp Glu Asp Glu
805 810 815
Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys Thr Arg His Tyr Phe Ile
820 825 830
Ala Ala Val Glu Arg Leu Trp Asp Tyr Gly Met Ser Ser Ser Pro His
835 840 845
Val Leu Arg Asn Arg Ala Gln Ser Gly Ser Val Pro Gln Phe Lys Lys
850 855 860
Val Val Phe Gln Glu Phe Thr Asp Gly Ser Phe Thr Gln Pro Leu Tyr
865 870 875 880
Arg Gly Glu Leu Asn Glu His Leu Gly Leu Leu Gly Pro Tyr Ile Arg
885 890 895
Ala Glu Val Glu Asp Asn Ile Met Val Thr Phe Arg Asn Gln Ala Ser
900 905 910
Arg Pro Tyr Ser Phe Tyr Ser Ser Leu Ile Ser Tyr Glu Glu Asp Gln
915 920 925
Arg Gln Gly Ala Glu Pro Arg Lys Asn Phe Val Lys Pro Asn Glu Thr
930 935 940
Lys Thr Tyr Phe Trp Lys Val Gln His His Met Ala Pro Thr Lys Asp
945 950 955 960
Glu Phe Asp Cys Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu
965 970 975
Lys Asp Val His Ser Gly Leu Ile Gly Pro Leu Leu Val Cys His Thr
980 985 990
Asn Thr Leu Asn Pro Ala His Gly Arg Gln Val Thr Val Gln Glu Phe
995 1000 1005
Ala Leu Phe Phe Thr Ile Phe Asp Glu Thr Lys Ser Trp Tyr Phe
1010 1015 1020
Thr Glu Asn Met Glu Arg Asn Cys Arg Ala Pro Cys Asn Ile Gln
1025 1030 1035
Met Glu Asp Pro Thr Phe Lys Glu Asn Tyr Arg Phe His Ala Ile
1040 1045 1050
Asn Gly Tyr Ile Met Asp Thr Leu Pro Gly Leu Val Met Ala Gln
1055 1060 1065
Asp Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser Asn Glu
1070 1075 1080
Asn Ile His Ser Ile His Phe Ser Gly His Val Phe Thr Val Arg
1085 1090 1095
Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr Pro Gly
1100 1105 1110
Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Ala Gly Ile Trp
1115 1120 1125
Arg Val Glu Cys Leu Ile Gly Glu His Leu His Ala Gly Met Ser
1130 1135 1140
Thr Leu Phe Leu Val Tyr Ser Asn Lys Cys Gln Thr Pro Leu Gly
1145 1150 1155
Met Ala Ser Gly His Ile Arg Asp Phe Gln Ile Thr Ala Ser Gly
1160 1165 1170
Gln Tyr Gly Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr Ser
1175 1180 1185
Gly Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro Phe Ser Trp Ile
1190 1195 1200
Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Lys Thr
1205 1210 1215
Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln Phe
1220 1225 1230
Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr Tyr Arg
1235 1240 1245
Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe Gly Asn Val Asp
1250 1255 1260
Ser Ser Gly Ile Lys His Asn Ile Phe Asn Pro Pro Ile Ile Ala
1265 1270 1275
Arg Tyr Ile Arg Leu His Pro Thr His Tyr Ser Ile Arg Ser Thr
1280 1285 1290
Leu Arg Met Glu Leu Met Gly Cys Asp Leu Asn Ser Cys Ser Met
1295 1300 1305
Pro Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln Ile Thr
1310 1315 1320
Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro Ser
1325 1330 1335
Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg Pro
1340 1345 1350
Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe Gln Lys
1355 1360 1365
Thr Met Lys Val Thr Gly Val Thr Thr Gln Gly Val Lys Ser Leu
1370 1375 1380
Leu Thr Ser Met Tyr Val Lys Glu Phe Leu Ile Ser Ser Ser Gln
1385 1390 1395
Asp Gly His Gln Trp Thr Leu Phe Phe Gln Asn Gly Lys Val Lys
1400 1405 1410
Val Phe Gln Gly Asn Gln Asp Ser Phe Thr Pro Val Val Asn Ser
1415 1420 1425
Leu Asp Pro Pro Leu Leu Thr Arg Tyr Leu Arg Ile His Pro Gln
1430 1435 1440
Ser Trp Val His Gln Ile Ala Leu Arg Met Glu Val Leu Gly Cys
1445 1450 1455
Glu Ala Gln Asp Leu Tyr
1460
<210> 8
<211> 50
<212> DNA
<213> artificial sequence
<220>
<223>primers F 1
<400> 8
ggccggactg ctggcttctt ctagagccgc cacaaggcgg tactatctgg 50
<210> 9
<211> 24
<212> DNA
<213> artificial sequence
<220>
<223>primers F 2
<400> 9
ggaagatctc caggcttgcc tgac 24
<210> 10
<211> 25
<212> DNA
<213> artificial sequence
<220>
<223>primers F 3
<400> 10
cccaagcttg ccgccaccat gacca 25
<210> 11
<211> 896
<212> DNA
<213> artificial sequence
<220>
<223>segment A
<400> 11
ggccggactg ctggcttctt ctagagccgc cacaaggcgg tactatctgg gcgctgtgga 60
actgtcatgg gattacatgc agtccgacct gggagagctg ccagtggacg ctcgatttcc 120
ccctcgtgtc cctaagagct tcccattcaa cacatctgtg gtctataaga aaacactgtt 180
cgtggagttt actgatcacc tgttcaacat cgccaagcct aggccaccct ggatgggact 240
gctgggacca actatccagg ctgaggtgta cgacaccgtg gtcattacac tgaaaaacat 300
ggcatcacac ccagtgtccc tgcatgccgt gggggtctct tactggaagg ctagtgaagg 360
tgcagagtat gacgatcaga catctcagcg ggaaaaagag gacgataagg tgtttcccgg 420
cggatcccat acttacgtgt ggcaggtcct gaaagagaat ggccccatgg cttctgatcc 480
tctgtgcctg acctactctt atctgagtca cgtggacctg gtcaaggatc tgaactccgg 540
gctgatcggt gcactgctgg tgtgcagaga agggagcctg gccaaggaga aaacccagac 600
actgcataag ttcattctgc tgttcgccgt gtttgacgag ggtaaatcat ggcactccga 660
gaccaagaac tccctgatgc aggacagaga tgcagctagc gcccgagctt ggccaaaaat 720
gcatacagtg aacggctacg tcaataggag tctgcccggc ctgatcggat gtcaccggaa 780
gtccgtgtat tggcatgtca tcgggatggg taccacaccc gaagtgcact ctattttcct 840
ggagggacat acctttctgg tccgaaacca ccgtcaggca agcctggaga tctgaa 896
<210> 12
<211> 69
<212> DNA
<213> artificial sequence
<220>
<223>segment B
<400> 12
aagcttgccg ccaccatgac cagactgacc gtgctggctc tgctggccgg actgctggct 60
tcttctaga 69
<210> 13
<211> 943
<212> DNA
<213> artificial sequence
<220>
<223>segment C
<400> 13
cccaagcttg ccgccaccat gaccagactg accgtgctgg ctctgctggc cggactgctg 60
gcttcttcta gagccgccac aaggcggtac tatctgggcg ctgtggaact gtcatgggat 120
tacatgcagt ccgacctggg agagctgcca gtggacgctc gatttccccc tcgtgtccct 180
aagagcttcc cattcaacac atctgtggtc tataagaaaa cactgttcgt ggagtttact 240
gatcacctgt tcaacatcgc caagcctagg ccaccctgga tgggactgct gggaccaact 300
atccaggctg aggtgtacga caccgtggtc attacactga aaaacatggc atcacaccca 360
gtgtccctgc atgccgtggg ggtctcttac tggaaggcta gtgaaggtgc agagtatgac 420
gatcagacat ctcagcggga aaaagaggac gataaggtgt ttcccggcgg atcccatact 480
tacgtgtggc aggtcctgaa agagaatggc cccatggctt ctgatcctct gtgcctgacc 540
tactcttatc tgagtcacgt ggacctggtc aaggatctga actccgggct gatcggtgca 600
ctgctggtgt gcagagaagg gagcctggcc aaggagaaaa cccagacact gcataagttc 660
attctgctgt tcgccgtgtt tgacgagggt aaatcatggc actccgagac caagaactcc 720
ctgatgcagg acagagatgc agctagcgcc cgagcttggc caaaaatgca tacagtgaac 780
ggctacgtca ataggagtct gcccggcctg atcggatgtc accggaagtc cgtgtattgg 840
catgtcatcg ggatgggtac cacacccgaa gtgcactcta ttttcctgga gggacatacc 900
tttctggtcc gaaaccaccg tcaggcaagc ctggagatct gaa 943
<210> 14
<211> 937
<212> DNA
<213> artificial sequence
<220>
<223>segment D
<400> 14
aagcttgccg ccaccatgac cagactgacc gtgctggctc tgctggccgg actgctggct 60
tcttctagag ccgccacaag gcggtactat ctgggcgctg tggaactgtc atgggattac 120
atgcagtccg acctgggaga gctgccagtg gacgctcgat ttccccctcg tgtccctaag 180
agcttcccat tcaacacatc tgtggtctat aagaaaacac tgttcgtgga gtttactgat 240
cacctgttca acatcgccaa gcctaggcca ccctggatgg gactgctggg accaactatc 300
caggctgagg tgtacgacac cgtggtcatt acactgaaaa acatggcatc acacccagtg 360
tccctgcatg ccgtgggggt ctcttactgg aaggctagtg aaggtgcaga gtatgacgat 420
cagacatctc agcgggaaaa agaggacgat aaggtgtttc ccggcggatc ccatacttac 480
gtgtggcagg tcctgaaaga gaatggcccc atggcttctg atcctctgtg cctgacctac 540
tcttatctga gtcacgtgga cctggtcaag gatctgaact ccgggctgat cggtgcactg 600
ctggtgtgca gagaagggag cctggccaag gagaaaaccc agacactgca taagttcatt 660
ctgctgttcg ccgtgtttga cgagggtaaa tcatggcact ccgagaccaa gaactccctg 720
atgcaggaca gagatgcagc tagcgcccga gcttggccaa aaatgcatac agtgaacggc 780
tacgtcaata ggagtctgcc cggcctgatc ggatgtcacc ggaagtccgt gtattggcat 840
gtcatcggga tgggtaccac acccgaagtg cactctattt tcctggaggg acataccttt 900
ctggtccgaa accaccgtca ggcaagcctg gagatct 937
<210> 15
<211> 6117
<212> DNA
<213> artificial sequence
<220>
<223>segment E
<400> 15
gatctctcct attaccttcc tgacagccca gactctgctg atggatctgg ggcagttcct 60
gctgttttgc cacatctcca gccaccagca tgatggtatg gaggcatacg tgaaagtgga 120
ctcctgtccc gaggaacctc agctgagaat gaagaacaat gaggaagccg aagactatga 180
cgatgacctg actgactccg agatggatgt ggtccgcttc gatgacgata actccccctc 240
cttcatccag attcgaagcg tggccaagaa acaccccaag acctgggtcc attacatcgc 300
agccgaggaa gaggactggg attatgcacc actggtgctg gcaccagacg acaggtccta 360
caaatctcag tatctgaaca atgggcctca gaggatcggt cggaagtaca agaaagtgcg 420
attcatggcc tataccgatg aaacatttaa gactcgtgaa gctatccagc acgagtccgg 480
gattctgggt ccactgctgt acggcgaagt gggagacact ctgctgatca tcttcaagaa 540
ccaggctagc aggccttaca atatctatcc acatggcatt accgatgtgc ggcctctgta 600
ctctagacgc ctgccaaagg gcgtcaaaca cctgaaggac ttcccaatcc tgcccggaga 660
aatcttcaag tataaatgga ctgtcaccgt cgaggatgga cccactaagt ctgaccctag 720
gtgcctgacc cggtactatt ctagtttcgt gaatatggaa agggatctgg cctccgggct 780
gatcggtcca ctgctgattt gttacaaaga gtctgtggat cagcgaggca accagatcat 840
gagtgacaag cgtaatgtga ttctgttctc cgtctttgac gaaaacagaa gctggtatct 900
gaccgagaac atccagaggt tcctgcctaa tccagcaggc gtgcagctgg aagatcccga 960
gtttcaggcc tcaaacatca tgcattccat taatggatac gtgttcgaca gtctgcagct 1020
gtcagtgtgc ctgcacgagg tcgcctactg gtatatcctg tccattgggg ctcagacaga 1080
tttcctgtcc gtgttcttta gcggttacac tttcaagcat aagatggtct acgaggacac 1140
actgactctg ttcccttttt ctggcgaaac cgtgtttatg agtatggaga atccaggcct 1200
gtggatcctg ggatgccaca acagcgattt ccgaaatcgt ggcatgactg ctctgctgaa 1260
agtgtcatcc tgtgacaaga acaccggaga ctactatgaa gatagctacg aggacatctc 1320
tgcttatctg ctgagtaaga acaatgcaat tgaacccagg tcttttagtc agaactctcg 1380
gcatcctagt cagaatcctc cagtgctgaa gagacaccag cgcgagatca ctagaactac 1440
cctgcagagt gatcaggaag agatcgacta cgacgatacc atttccgtgg aaatgaagaa 1500
agaggacttc gatatctatg acgaagatga gaaccagagt cctagatcat tccagaagaa 1560
aacccgccat tactttattg ctgcagtgga gcgcctgtgg gattatggga tgagctctag 1620
tccccacgtg ctgaggaatc gggcccagtc aggttccgtc cctcagttca agaaagtggt 1680
cttccaggag tttacagacg gcagctttac tcagcctctg tacagaggag aactgaacga 1740
gcacctgggc ctgctgggac catatatccg cgccgaagtg gaggataaca ttatggtcac 1800
cttccgaaat caggcttcac gtccctactc cttttattca tccctgatct cttacgaaga 1860
ggaccagcga cagggcgctg aaccccgtaa aaacttcgtg aagcctaatg agaccaaaac 1920
atacttttgg aaggtgcagc accatatggc ccctacaaaa gacgagttcg attgcaaggc 1980
atgggcctat ttttcagacg tggatctgga gaaggacgtg cactctgggc tgatcggtcc 2040
tctgctggtg tgccatacta acaccctgaa tccagctcac ggcaggcagg tgacagtcca 2100
ggagttcgca ctgttcttta ccatctttga tgagacaaag tcctggtact tcactgaaaa 2160
catggagcga aattgccgtg ctccatgtaa tattcagatg gaagacccca ccttcaagga 2220
gaactaccgg tttcatgcaa tcaatggcta tattatggat acactgccag gactggtgat 2280
ggcccaggac cagagaatcc gctggtacct gctgtccatg ggcagcaacg agaatatcca 2340
cagcattcat ttctctggac acgtgtttac agtccgcaag aaagaagagt ataaaatggc 2400
cctgtacaac ctgtatccag gggtgttcga aactgtcgag atgctgccca gcaaggctgg 2460
tatctggcga gtggaatgcc tgattgggga gcacctgcat gcaggcatgt caaccctgtt 2520
tctggtgtac tccaataagt gtcagacacc actggggatg gccagcggtc atatccgaga 2580
tttccagatt accgcttctg gccagtacgg acagtgggcc cccaagctgg ctaggctgca 2640
ctatagcggc tctatcaacg cctggagtac caaagagccc ttttcatgga ttaaggtgga 2700
cctgctggct cctatgatca ttcatgggat caaaacacag ggtgcacggc agaagttcag 2760
ctctctgtac atcagccagt tcatcatcat gtactctctg gatggaaaga aatggcagac 2820
atacagaggc aatagcacag gaactctgat ggtgttcttt ggcaacgtgg acagttcagg 2880
aatcaagcac aacattttca atccccctat cattgctagg tacatccggc tgcaccctac 2940
ccattattct attagaagta cactgcgcat ggaactgatg gggtgcgatc tgaacagttg 3000
ttcaatgcca ctgggtatgg agagtaaggc aatctcagac gcccagatta ccgcttccag 3060
ctacttcact aatatgtttg ctacctggtc ccctagcaaa gcaagactgc atctgcaggg 3120
caggagcaac gcatggcggc cacaggtgaa caatcccaag gagtggctgc aggtcgattt 3180
tcagaaaact atgaaggtga ccggcgtcac aactcaggga gtgaaatccc tgctgactag 3240
catgtatgtc aaggagttcc tgatctctag ttcacaggac ggacaccagt ggaccctgtt 3300
ctttcagaac gggaaggtga aagtcttcca gggtaatcag gatagtttta cacccgtggt 3360
caactcactg gacccacccc tgctgactag atacctgcgc atccaccctc agtcttgggt 3420
gcatcagatt gctctgagga tggaagtcct gggctgtgag gcacaggacc tgtattgata 3480
agaattcact ggccgtcgtt ttacaacgtc gtgactggga aaaccctggc gttacccaac 3540
ttaatcgcct tgcagcacat ccccctttcg ccagctggcg taatagcgaa gaggcccgca 3600
ccgatcgccc ttcccaacag ttgcgcagcc tgaatggcga atggcgcctg atgcggtatt 3660
ttctccttac gcatctgtgc ggtatttcac accgcatatg gtgcactctc agtacaatct 3720
gctctgatgc cgcatagtta agccagcccc gacacccgcc aacacccgct gacgcgccct 3780
gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc tccgggagct 3840
gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc gagacgaaag ggcctcgtga 3900
tacgcctatt tttataggtt aatgtcatga taataatggt ttcttagacg tcaggtggca 3960
cttttcgggg aaatgtgcgc ggaaccccta tttgtttatt tttctaaata cattcaaata 4020
tgtatccgct catgagacaa taaccctgat aaatgcttca ataatattga aaaaggaaga 4080
gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgcggca ttttgccttc 4140
ctgtttttgc tcacccagaa acgctggtga aagtaaaaga tgctgaagat cagttgggtg 4200
cacgagtggg ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc 4260
ccgaagaacg ttttccaatg atgagcactt ttaaagttct gctatgtggc gcggtattat 4320
cccgtattga cgccgggcaa gagcaactcg gtcgccgcat acactattct cagaatgact 4380
tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca gtaagagaat 4440
tatgcagtgc tgccataacc atgagtgata acactgcggc caacttactt ctgacaacga 4500
tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat gtaactcgcc 4560
ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga 4620
tgcctgtagc aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag 4680
cttcccggca acaattaata gactggatgg aggcggataa agttgcagga ccacttctgc 4740
gctcggccct tccggctggc tggtttattg ctgataaatc tggagccggt gagcgtgggt 4800
ctcgcggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct 4860
acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct gagataggtg 4920
cctcactgat taagcattgg taactgtcag accaagttta ctcatatata ctttagattg 4980
atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca 5040
tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga 5100
tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa 5160
aaccaccgct accagcggtg gtttgtttgc cggatcaaga gctaccaact ctttttccga 5220
aggtaactgg cttcagcaga gcgcagatac caaatactgt tcttctagtg tagccgtagt 5280
taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg ctaatcctgt 5340
taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac tcaagacgat 5400
agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca cagcccagct 5460
tggagcgaac gacctacacc gaactgagat acctacagcg tgagctatga gaaagcgcca 5520
cgcttcccga agggagaaag gcggacaggt atccggtaag cggcagggtc ggaacaggag 5580
agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagtcct gtcgggtttc 5640
gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg agcctatgga 5700
aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca 5760
tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc tttgagtgag 5820
ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc gaggaagcgg 5880
aagagcgccc aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat taatgcagct 5940
ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt aatgtgagtt 6000
agctcactca ttaggcaccc caggctttac actttatgct tccggctcgt atgttgtgtg 6060
gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat tacgcca 6117
<210> 16
<211> 4413
<212> DNA
<213> artificial sequence
<220>
<223>segment F
<400> 16
agcttgccgc caccatgacc agactgaccg tgctggctct gctggccgga ctgctggctt 60
cttctagagc cgccacaagg cggtactatc tgggcgctgt ggaactgtca tgggattaca 120
tgcagtccga cctgggagag ctgccagtgg acgctcgatt tccccctcgt gtccctaaga 180
gcttcccatt caacacatct gtggtctata agaaaacact gttcgtggag tttactgatc 240
acctgttcaa catcgccaag cctaggccac cctggatggg actgctggga ccaactatcc 300
aggctgaggt gtacgacacc gtggtcatta cactgaaaaa catggcatca cacccagtgt 360
ccctgcatgc cgtgggggtc tcttactgga aggctagtga aggtgcagag tatgacgatc 420
agacatctca gcgggaaaaa gaggacgata aggtgtttcc cggcggatcc catacttacg 480
tgtggcaggt cctgaaagag aatggcccca tggcttctga tcctctgtgc ctgacctact 540
cttatctgag tcacgtggac ctggtcaagg atctgaactc cgggctgatc ggtgcactgc 600
tggtgtgcag agaagggagc ctggccaagg agaaaaccca gacactgcat aagttcattc 660
tgctgttcgc cgtgtttgac gagggtaaat catggcactc cgagaccaag aactccctga 720
tgcaggacag agatgcagct agcgcccgag cttggccaaa aatgcataca gtgaacggct 780
acgtcaatag gagtctgccc ggcctgatcg gatgtcaccg gaagtccgtg tattggcatg 840
tcatcgggat gggtaccaca cccgaagtgc actctatttt cctggaggga catacctttc 900
tggtccgaaa ccaccgtcag gcaagcctgg agatctctcc tattaccttc ctgacagccc 960
agactctgct gatggatctg gggcagttcc tgctgttttg ccacatctcc agccaccagc 1020
atgatggtat ggaggcatac gtgaaagtgg actcctgtcc cgaggaacct cagctgagaa 1080
tgaagaacaa tgaggaagcc gaagactatg acgatgacct gactgactcc gagatggatg 1140
tggtccgctt cgatgacgat aactccccct ccttcatcca gattcgaagc gtggccaaga 1200
aacaccccaa gacctgggtc cattacatcg cagccgagga agaggactgg gattatgcac 1260
cactggtgct ggcaccagac gacaggtcct acaaatctca gtatctgaac aatgggcctc 1320
agaggatcgg tcggaagtac aagaaagtgc gattcatggc ctataccgat gaaacattta 1380
agactcgtga agctatccag cacgagtccg ggattctggg tccactgctg tacggcgaag 1440
tgggagacac tctgctgatc atcttcaaga accaggctag caggccttac aatatctatc 1500
cacatggcat taccgatgtg cggcctctgt actctagacg cctgccaaag ggcgtcaaac 1560
acctgaagga cttcccaatc ctgcccggag aaatcttcaa gtataaatgg actgtcaccg 1620
tcgaggatgg acccactaag tctgacccta ggtgcctgac ccggtactat tctagtttcg 1680
tgaatatgga aagggatctg gcctccgggc tgatcggtcc actgctgatt tgttacaaag 1740
agtctgtgga tcagcgaggc aaccagatca tgagtgacaa gcgtaatgtg attctgttct 1800
ccgtctttga cgaaaacaga agctggtatc tgaccgagaa catccagagg ttcctgccta 1860
atccagcagg cgtgcagctg gaagatcccg agtttcaggc ctcaaacatc atgcattcca 1920
ttaatggata cgtgttcgac agtctgcagc tgtcagtgtg cctgcacgag gtcgcctact 1980
ggtatatcct gtccattggg gctcagacag atttcctgtc cgtgttcttt agcggttaca 2040
ctttcaagca taagatggtc tacgaggaca cactgactct gttccctttt tctggcgaaa 2100
ccgtgtttat gagtatggag aatccaggcc tgtggatcct gggatgccac aacagcgatt 2160
tccgaaatcg tggcatgact gctctgctga aagtgtcatc ctgtgacaag aacaccggag 2220
actactatga agatagctac gaggacatct ctgcttatct gctgagtaag aacaatgcaa 2280
ttgaacccag gtcttttagt cagaactctc ggcatcctag tcagaatcct ccagtgctga 2340
agagacacca gcgcgagatc actagaacta ccctgcagag tgatcaggaa gagatcgact 2400
acgacgatac catttccgtg gaaatgaaga aagaggactt cgatatctat gacgaagatg 2460
agaaccagag tcctagatca ttccagaaga aaacccgcca ttactttatt gctgcagtgg 2520
agcgcctgtg ggattatggg atgagctcta gtccccacgt gctgaggaat cgggcccagt 2580
caggttccgt ccctcagttc aagaaagtgg tcttccagga gtttacagac ggcagcttta 2640
ctcagcctct gtacagagga gaactgaacg agcacctggg cctgctggga ccatatatcc 2700
gcgccgaagt ggaggataac attatggtca ccttccgaaa tcaggcttca cgtccctact 2760
ccttttattc atccctgatc tcttacgaag aggaccagcg acagggcgct gaaccccgta 2820
aaaacttcgt gaagcctaat gagaccaaaa catacttttg gaaggtgcag caccatatgg 2880
cccctacaaa agacgagttc gattgcaagg catgggccta tttttcagac gtggatctgg 2940
agaaggacgt gcactctggg ctgatcggtc ctctgctggt gtgccatact aacaccctga 3000
atccagctca cggcaggcag gtgacagtcc aggagttcgc actgttcttt accatctttg 3060
atgagacaaa gtcctggtac ttcactgaaa acatggagcg aaattgccgt gctccatgta 3120
atattcagat ggaagacccc accttcaagg agaactaccg gtttcatgca atcaatggct 3180
atattatgga tacactgcca ggactggtga tggcccagga ccagagaatc cgctggtacc 3240
tgctgtccat gggcagcaac gagaatatcc acagcattca tttctctgga cacgtgttta 3300
cagtccgcaa gaaagaagag tataaaatgg ccctgtacaa cctgtatcca ggggtgttcg 3360
aaactgtcga gatgctgccc agcaaggctg gtatctggcg agtggaatgc ctgattgggg 3420
agcacctgca tgcaggcatg tcaaccctgt ttctggtgta ctccaataag tgtcagacac 3480
cactggggat ggccagcggt catatccgag atttccagat taccgcttct ggccagtacg 3540
gacagtgggc ccccaagctg gctaggctgc actatagcgg ctctatcaac gcctggagta 3600
ccaaagagcc cttttcatgg attaaggtgg acctgctggc tcctatgatc attcatggga 3660
tcaaaacaca gggtgcacgg cagaagttca gctctctgta catcagccag ttcatcatca 3720
tgtactctct ggatggaaag aaatggcaga catacagagg caatagcaca ggaactctga 3780
tggtgttctt tggcaacgtg gacagttcag gaatcaagca caacattttc aatcccccta 3840
tcattgctag gtacatccgg ctgcacccta cccattattc tattagaagt acactgcgca 3900
tggaactgat ggggtgcgat ctgaacagtt gttcaatgcc actgggtatg gagagtaagg 3960
caatctcaga cgcccagatt accgcttcca gctacttcac taatatgttt gctacctggt 4020
cccctagcaa agcaagactg catctgcagg gcaggagcaa cgcatggcgg ccacaggtga 4080
acaatcccaa ggagtggctg caggtcgatt ttcagaaaac tatgaaggtg accggcgtca 4140
caactcaggg agtgaaatcc ctgctgacta gcatgtatgt caaggagttc ctgatctcta 4200
gttcacagga cggacaccag tggaccctgt tctttcagaa cgggaaggtg aaagtcttcc 4260
agggtaatca ggatagtttt acacccgtgg tcaactcact ggacccaccc ctgctgacta 4320
gatacctgcg catccaccct cagtcttggg tgcatcagat tgctctgagg atggaagtcc 4380
tgggctgtga ggcacaggac ctgtattgat aag 4413
<210> 17
<211> 6893
<212> DNA
<213> artificial sequence
<220>
<223>segment G
<400> 17
aattcattga tcataatcag ccataccaca tttgtagagg ttttacttgc tttaaaaaac 60
ctcccacacc tccccctgaa cctgaaacat aaaatgaatg caattgttgt tgttaacttg 120
tttattgcag cttataatgg ttacaaataa agcaatagca tcacaaattt cacaaataaa 180
gcattttttt cactgcattc tagttgtggt ttgtccaaac tcatcaatgt atcttatcat 240
gtctggcggc cgcgacctgc aggcgcagaa ctggtaggta tggaagatcc ctcgagatcc 300
attgtgctgg cggtaggcga gcagcgcctg cctgaagctg cgggcattcc cgatcagaaa 360
tgagcgccag tcgtcgtcgg ctctcggcac cgaatgcgta tgattctccg ccagcatggc 420
ttcggccagt gcgtcgagca gcgcccgctt gttcctgaag tgccagtaaa gcgccggctg 480
ctgaaccccc aaccgttccg ccagtttgcg tgtcgtcaga ccgtctacgc cgacctcgtt 540
caacaggtcc agggcggcac ggatcactgt attcggctgc aactttgtca tgcttgacac 600
tttatcactg ataaacataa tatgtccacc aacttatcag tgataaagaa tccgcgccag 660
cacaatggat ctcgaggtcg agggatctct agaggatcct ctacgccgga cgcatcgtgg 720
ccggcatcac cggcgccaca ggtgcggttg ctggcgccta tatcgccgac atcaccgatg 780
gggaagatcg ggctcgccac ttcgggctca tgagcgcttg tttcggcgtg ggtatggtgg 840
caggccccgt ggccggggga ctgttgggcg ccatctcctt gcatgcacca ttccttgcgg 900
cggcggtgct caacggcctc aacctactac tgggctgctt cctaatgcag gagtcgcata 960
agggagagcg tcgacctcgg gccgcgttgc tggcgttttt ccataggctc cgcccccctg 1020
acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa 1080
gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc 1140
ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac 1200
gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac 1260
cccccgttca gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg 1320
taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt 1380
atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa 1440
cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct 1500
cttgatccgg caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga 1560
ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg 1620
ctcagtggaa cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct 1680
tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt 1740
aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc 1800
tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg 1860
gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag 1920
atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt 1980
tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag 2040
ttaatagttt gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt 2100
ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca 2160
tgttgtgcaa aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg 2220
ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat 2280
ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta 2340
tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca 2400
gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct 2460
taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat 2520
cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa 2580
agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt 2640
gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa 2700
ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa 2760
ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc tgatggctct 2820
ttgcggcacc catcgttcgt aatgttccgt ggcaccgagg acaaccctca agagaaaatg 2880
taatcacact ggctcacctt cgggtgggcc tttctgcgtt tataaggaga cactttatgt 2940
ttaagaaggt tggtaaattc cttgcggctt tggcagccaa gctagatccg gctgtggaat 3000
gtgtgtcagt tagggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 3060
atgcatctca attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga 3120
agtatgcaaa gcatgcatct caattagtca gcaaccatag tcccgcccct aactccgccc 3180
atcccgcccc taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt 3240
tttatttatg cagaggccga ggccgcctcg gcctctgagc tattccagaa gtagtgagga 3300
ggcttttttg gaggcctagg cttttgcaaa aagctagctt ggggccaccg ctcagagcac 3360
cttccaccat ggccacctca gcaagttccc acttgaacaa aaacatcaag caaatgtact 3420
tgtgcctgcc ccagggtgag aaagtccaag ccatgtatat ctgggttgat ggtactggag 3480
aaggactgcg ctgcaaaacc cgcaccctgg actgtgagcc caagtgtgta gaagagttac 3540
ctgagtggaa ttttgatggc tctagtacct ttcagtctga gggctccaac agtgacatgt 3600
atctcagccc tgttgccatg tttcgggacc ccttccgcag agatcccaac aagctggtgt 3660
tctgtgaagt tttcaagtac aaccggaagc ctgcagagac caatttaagg cactcgtgta 3720
aacggataat ggacatggtg agcaaccagc acccctggtt tggaatggaa caggagtata 3780
ctctgatggg aacagatggg cacccttttg gttggccttc caatggcttt cctgggcccc 3840
aaggtccgta ttactgtggt gtgggcgcag acaaagccta tggcagggat atcgtggagg 3900
ctcactaccg cgcctgcttg tatgctgggg tcaagattac aggaacaaat gctgaggtca 3960
tgcctgccca gtgggagttc caaataggac cctgtgaagg aatccgcatg ggagatcatc 4020
tctgggtggc ccgtttcatc ttgcatcgag tatgtgaaga ctttggggta atagcaacct 4080
ttgaccccaa gcccattcct gggaactgga atggtgcagg ctgccatacc aactttagca 4140
ccaaggccat gcgggaggag aatggtctga agcacatcga ggaggccatc gagaaactaa 4200
gcaagcggca ccggtaccac attcgagcct acgatcccaa ggggggcctg gacaatgccc 4260
gtcgtctgac tgggttccac gaaacgtcca acatcaacga cttttctgct ggtgtcgcca 4320
atcgcagtgc cagcatccgc attccccgga ctgtcggcca ggagaagaaa ggttactttg 4380
aagaccgccg cccctctgcc aattgtgacc cctttgcagt gacagaagcc atcgtccgca 4440
catgccttct caatgagact ggcgacgagc ccttccaata caaaaactaa ttagactttg 4500
agtgatcttg agcctttcct agttcatccc accccgcccc agagagatct ttgtgaagga 4560
accttacttc tgtggtgtga cataattgga caaactacct acagagattt aaagctctaa 4620
ggtaaatata aaatttttaa gtgtataatg tgttaaacta ctgattctaa ttgtttgtgt 4680
attttagatt ccaacctatg gaactgatga atgggagcag tggtggaatg cctttaatga 4740
ggaaaacctg ttttgctcag aagaaatgcc atctagtgat gatgaggcta ctgctgactc 4800
tcaacattct actcctccaa aaaagaagag aaaggtagaa gaccccaagg actttccttc 4860
agaattgcta agttttttga gtcatgctgt gtttagtaat agaactcttg cttgctttgc 4920
tatttacacc acaaaggaaa aagctgcact gctatacaag aaaattatgg aaaaatattc 4980
tgtaaccttt ataagtaggc ataacagtta taatcataac atactgtttt ttcttactcc 5040
acacaggcat agagtgtctg ctattaataa ctatgctcaa aaattgtgta cctttagctt 5100
tttaatttgt aaaggggtta ataaggaata tttgatgtat agtgccttga ctagagatca 5160
taatcagcca taccacattt gtagaggttt tacttgcttt aaaaaacctc ccacacctcc 5220
ccctgaacct gaaacataaa atgaatgcaa ttgttgttgt taacttgttt attgcagctt 5280
ataatggtta caaataaagc aatagcatca caaatttcac aaataaagca tttttttcac 5340
tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc tggatctcta 5400
gcttcgtgtc aaggacggtg aggcgcgcct actgagtcat tagggacttt ccaatgggtt 5460
ttgcccagta cataaggtca ataggggtga atcaacagga aagtcccatt ggagccaagt 5520
acactgagtc aatagggact ttccattggg ttttgcccag tacaaaaggt caataggggg 5580
tgagtcaatg ggtttttccc attattggca cgtacataag gtcaataggg gtgagtcatt 5640
gggtttttcc agccaattta attaaaacgc catgtacttt cccaccattg acgtcaatgg 5700
gctattgaaa ctaatgcaac gtgaccttta aacggtactt tcccatagct gattaatggg 5760
aaagtaccgt tctcgagcca atacacgtca atgggaagtg aaagggcagc caaaacgtaa 5820
caccgccccg gttttcccct ggaaattcca tattggcacg cattctattg gctgagctgc 5880
gttctacgtg ggtataagag gcgcgaccag cgtcggtacc gtcgcagtct tcggtctgac 5940
caccgtagaa cgcagcctca ggacctccat agaagacacc gggaccgatc cagcctccgc 6000
ggccgggaac ggtgcattgg aacgcggatt ccccgtgcca agagtgacgt aagtaccgcc 6060
tatagagtct ataggcccac ccccttggct tcttatgcat gctatactgt ttttggcttg 6120
gggtctatac acccccgctt cctcatgtta taggtgatgg tatagcttag cctataggtg 6180
tgggttattg accattattg accactcccc tattggtgac gatactttcc attactaatc 6240
cataacatgg ctctttgcca caactctctt tattggctat atgccaatac actgtccttc 6300
agagactgac acggactctg tatttttaca ggatggggtc tcatttatta tttacaaatt 6360
cacatataca acaccaccgt ccccagtgcc cgcagttttt attaaacata acgtgggatc 6420
tccacgcgaa tctcgggtac gtgttccgga catgggctct tctccggtag cggcggagct 6480
tctacatccg agccctgctc ccatgcctcc agcgactcat ggtcgctcgg cagctccttg 6540
ctcctaacag tggaggccag acttaggcac agcacgatgc ccaccaccac cagtgtgccg 6600
cacaaggccg tggcggtagg gtatgtgtct gaaaatgagc tcggggagcg ggcttgcacc 6660
gctgacgcat ttggaagact taaggcagcg gcagaagaag atgcaggcag ctgagttgtt 6720
gtgttctgat aagagtcaga ggtaactccc gttgcggtgc tgttaacggt ggagggcagt 6780
gtagtctgag cagtactcgt tgctgccgcg cgcgccacca gacataatag ctgacagact 6840
aacagactgt tcctttccat gggtcttttc tgcagtcacc gtccttgaca cga 6893

Claims (10)

1. a kind of method for improving recombinant human blood coagulation factor VII I high efficient expression, comprising the following steps:
(1) building of recombination, the recombination include signal peptide gene and rhFVIII gene;
(2) above-mentioned recombination segment is inserted into plasmid, obtains recombinant plasmid;
(3) above-mentioned recombinant plasmid is subjected to PvuI linearisation, electricity is gone in mammalian cell, identified and determination of activity, sieve Select positive cell strain;
(4) by it is above-mentioned screen positive cell strain is seeded in cell culture medium, cultivate 4-5 days, added into cell culture medium External source fetal calf serum collects culture solution and carries out determination of activity;It is characterized in that, the additional amount of the fetal calf serum is 2-6%.
2. the method according to claim 1, wherein the nucleotides sequence of rhFVIII is classified as in the step (1) SEQ ID NO:1.
3. the method according to claim 1, wherein signal peptide is reddish black killing after optimization in the step (1) Former albumen (Azu) before element, nucleotides sequence are classified as SEQ ID NO:4, and obtained recombination is Azu-rhFVIII, nucleotides sequence It is classified as SEQ ID NO:6.
4. according to the method described in claim 3, it is characterized in that, the amino acid sequence of the recombination Azu-rhFVIII For SEQ ID NO:7.
5. being obtained the method according to claim 1, wherein the plasmid in the step (2) is pXC17.4 Recombinant expression plasmid is pXC17.4-Azu-rhFVIII.
6. the method according to claim 1, wherein the mammalian cell in the step (3) is Chinese storehouse Mouse egg cell CHOK1SV-KO.
7. the method according to claim 1, wherein cell culture medium is CD CHO AGT in the step (4) Culture medium.
8. the method according to claim 1, wherein the additional amount of fetal calf serum is 3- in the step (4) 5%.
9. the method according to claim 1, wherein the additional amount of fetal calf serum is 3% in the step (4).
10. the method according to claim 1, wherein in the step (3) positive cell strain screening technique Are as follows: electricity is turned into cell inoculation into serum free medium, after 35-37 DEG C is cultivated 1 day, supernatant is abandoned in centrifugation, is added toward cell precipitation Enter preheated culture medium (50 μm of ol/L MSX CD CHO AGT culture mediums) resuspension, re-suspension liquid is transferred to conical flask and continues to train It supports, cultivates to after 10 days, sampling screens to obtain positive cell strain CHOK1SV-KO/pXC17.4-Azu- by PCR and activity identification rhFVIII。
CN201711346319.XA 2017-12-15 2017-12-15 A method of improving recombinant human blood coagulation factor VII I high efficient expression Pending CN109929029A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711346319.XA CN109929029A (en) 2017-12-15 2017-12-15 A method of improving recombinant human blood coagulation factor VII I high efficient expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711346319.XA CN109929029A (en) 2017-12-15 2017-12-15 A method of improving recombinant human blood coagulation factor VII I high efficient expression

Publications (1)

Publication Number Publication Date
CN109929029A true CN109929029A (en) 2019-06-25

Family

ID=66979461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711346319.XA Pending CN109929029A (en) 2017-12-15 2017-12-15 A method of improving recombinant human blood coagulation factor VII I high efficient expression

Country Status (1)

Country Link
CN (1) CN109929029A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111269306A (en) * 2020-03-12 2020-06-12 蓝怡科技集团股份有限公司 Art V1 recombinant protein and preparation method and application thereof
CN111808863A (en) * 2020-06-23 2020-10-23 康霖生物科技(杭州)有限公司 Codon-optimized coagulation factor VIII gene and construct thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351586A1 (en) * 1988-06-24 1990-01-24 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Plasmids containing a chicken beta-actin promoter and a human factor VIII:C gene, transformants and processes for preparing human factor VIII:C
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CN101160392A (en) * 2005-04-20 2008-04-09 惠氏公司 Mammalian expression systems
CN104519912A (en) * 2012-08-13 2015-04-15 诺和诺德A/S(股份有限公司) Liquid factor VIII formulations
CN106589129A (en) * 2016-12-30 2017-04-26 上海近岸生物科技有限公司 Three-function molecule combining CD19, CD3 and CD28 and application of three-function molecule

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351586A1 (en) * 1988-06-24 1990-01-24 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Plasmids containing a chicken beta-actin promoter and a human factor VIII:C gene, transformants and processes for preparing human factor VIII:C
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CN101160392A (en) * 2005-04-20 2008-04-09 惠氏公司 Mammalian expression systems
US20090214513A1 (en) * 2005-04-20 2009-08-27 Wyeth Mammalian expression systems
CN104519912A (en) * 2012-08-13 2015-04-15 诺和诺德A/S(股份有限公司) Liquid factor VIII formulations
CN106589129A (en) * 2016-12-30 2017-04-26 上海近岸生物科技有限公司 Three-function molecule combining CD19, CD3 and CD28 and application of three-function molecule

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111269306A (en) * 2020-03-12 2020-06-12 蓝怡科技集团股份有限公司 Art V1 recombinant protein and preparation method and application thereof
CN111808863A (en) * 2020-06-23 2020-10-23 康霖生物科技(杭州)有限公司 Codon-optimized coagulation factor VIII gene and construct thereof
CN111808863B (en) * 2020-06-23 2021-05-28 康霖生物科技(杭州)有限公司 Codon-optimized coagulation factor VIII gene and construct thereof

Similar Documents

Publication Publication Date Title
CN108753824B (en) Viral vectors for the treatment of retinal dystrophy
KR102267412B1 (en) Rna trnascription vector and uses thereof
KR101819803B1 (en) Platelet targeted treatment
KR20170003939A (en) Anti-human papillomavirus 16 e7 t cell receptors
CA2688804A1 (en) Polycistronic vector for human induced pluripotent stem cell production
KR101949293B1 (en) Complement factor b analogs and their uses
PT770136E (en) Method for selecting high-expressing host cells
CN108136048A (en) The system synthesis of levodopa and adjusting
CN112501101B (en) High-yield strain of natural herbicide thaxtomins as well as preparation method and application thereof
CN109929029A (en) A method of improving recombinant human blood coagulation factor VII I high efficient expression
AU2023241362A1 (en) Chimeric opsin GPCR proteins
CN110484565A (en) A kind of suicide gene system and its application based on gland relevant viral vector transformation
CN115074369B (en) Adeno-associated virus vector expressing full-length ABCA4 gene and application thereof
CN111440774A (en) Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP
KR102510154B1 (en) Visceral adipose tissue macrophage-targeted gene/carrier complex for preventing or treating obesity-induced type II diabetes
TW202317753A (en) Armed chimeric receptors and methods of use thereof
KR102570821B1 (en) Recombinant viral vector and pharmaceutical composition incluidng thereof
KR20160079868A (en) Viral vector manufacture
CN112831524B (en) Artificially modified recombinant adenovirus vector, virus packaged by same and application thereof
KR102163667B1 (en) Composite containing gene and gene delivery system for prevent or treatment of inflammatory disease
CN107619821B (en) CIK modified by similar chimeric antigen receptor and preparation method and application thereof
CN115335396A (en) Chimeric antigen receptor targeting CD33
CN112980819A (en) Construction method and application of retinitis pigmentosa animal model
TW202302858A (en) Insulin gene therapy to treat diabetes
CN114196712B (en) Method for producing L-ornithine by immobilized enzyme method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190625